ArticleEuropean journal of nuclear medicine and molecular imaging2019
Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany.
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Impact of preoperative [Annals of nuclear medicine · 2024Article
- How [Cancers · 2024Article
- Quality and consistency of clinical practice guideline recommendations for PET/CT and PET: a systematic appraisal.European radiology · 2023Article
- Influence of [Diagnostics (Basel, Switzerland) · 2023Article
- How [18F]-FDG-PET/CT Affects Clinical Management of Patients with Germ Cell Tumors in the Real World.Cancers · 2023Article
- A whole-body FDG-PET/CT Dataset with manually annotated Tumor Lesions.Scientific data · 2022Article
- Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Weakly supervised segmentation of tumor lesions in PET-CT hybrid imaging.Journal of medical imaging (Bellingham, Wash.) · 2021Article
- Impact of unknown incidental findings in PET/CT examinations of patients with proven or suspected vascular graft or endograft infections.Scientific reports · 2021Article
- Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients.Diagnostics (Basel, Switzerland) · 2021Article
- Impact ofBJR open · 2021Article
- Observational
- Influence ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Treatment outcome after radiochemotherapy in anal cancer patients staged withClinical and translational radiation oncology · 2020Article
- Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoingCancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study.European radiology · 2020Article
- Imaging of pediatric cutaneous melanoma.Pediatric radiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to evaluate the impact of PET/CT on clinical management of cancer patients based on a prospective data registry. The study was developed to inform consultations with public health insurances on PET/CT coverage.
methodsWe evaluated a prospective patient cohort having a clinically indicated PET/CT at a single German University Center from April 2013 to August 2016. The registry collected questionnaire data from requesting physicians on intended patient management before and after PET/CT. A total of 4,504 patients with 5,939 PET/CT examinations were enrolled in the registry, resulting in evaluable data from 3,724 patients receiving 4,754 scans. The impact of PET/CT on patient management was assessed across 22 tumor types, for different indications (diagnosis, staging, suspected recurrence) and different categories of management including treatment (curative or palliative) and non-treatment (watchful waiting, additional imaging, invasive tests).
resultsThe most frequent PET/CT indication was tumor staging (59.7%). Melanoma, lung cancer, lymphoma, neuroendocrine tumor and prostate cancer accounted for 70% of cases. Overall, the use of PET/CT resulted in a 37.1% change of clinical management (95% CI, 35.7-38.5), most frequently (30.6%) from an intended non-treatment strategy before PET/CT to active treatment after PET/CT. The frequency of changes ranged from 28.3% for head and neck cancers up to 46.0% for melanomas. The impact of PET/CT was greatest in reducing demands for additional imaging which decreased from 66.1% before PET/CT to 6.1% after PET/CT. Pre-PET/CT planned invasive tests could be avoided in 72.7% of cases. The treatment goal changed after PET/CT in 21.7% of cases, in twice as many cases from curative to palliative therapy than vice versa.
conclusionsThe data of this large prospective registry confirm that physicians often change their intended management on the basis of PET/CT by initiating treatment and reducing additional imaging as well as invasive tests. This applies to various cancer types and indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.